ReviewDialogues in clinical neuroscience2014
Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder.
Review in Dialogues in clinical neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Neural, Anti-Inflammatory, and Clinical Effects of Transauricular Vagus Nerve Stimulation in Major Depressive Disorder: A Systematic Review.The international journal of neuropsychopharmacology · 2024Pooled it
- Identifying transdiagnostic neurobiomarkers for precision major psychiatric disordersJournal of translational internal medicine · 2026Article
- Article
- Frontiers in broiler chicken welfare: adopting early detection of intestinal integrity loss in broiler welfare assessment protocols.Frontiers in veterinary science · 2025Article
- A Microbial-Based Approach to Mental Health: The Potential of Probiotics in the Treatment of Depression.Nutrients · 2023Review
- Dimensions of depressive symptomatology in mothers derived from factor analyses.Archives of gynecology and obstetrics · 2022Article
- Turning data into better mental health: Past, present, and future.Frontiers in digital health · 2022Review
- Plasma Metabolomics Profiling of Metabolic Pathways Affected by Major Depressive Disorder.Frontiers in psychiatry · 2021Article
- Prospective testing of a neurophysiologic biomarker for treatment decisions in major depressive disorder: The PRISE-MD trial.Journal of psychiatric research · 2020Article
- Changes in Functional Connectivity Predict Outcome of Repetitive Transcranial Magnetic Stimulation Treatment of Major Depressive Disorder.Cerebral cortex (New York, N.Y. : 1991) · 2019Article
- Resting-State Quantitative Electroencephalography Demonstrates Differential Connectivity in Adolescents with Major Depressive Disorder.Journal of child and adolescent psychopharmacology · 2019Article
- Review
- Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics study.Translational psychiatry · 2018Article
- Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient.The international journal of neuropsychopharmacology · 2018Review
- Comparison of Electroencephalography (EEG) Coherence between Major Depressive Disorder (MDD) without Comorbidity and MDD Comorbid with Internet Gaming Disorder.Journal of Korean medical science · 2017Article
- Brain arousal regulation as response predictor for antidepressant therapy in major depression.Scientific reports · 2017Article
- The Importance of Endophenotypes to Evaluate the Relationship between Genotype and External Phenotype.International journal of molecular sciences · 2017Review
- Multi-Level Integration of Environmentally Perturbed Internal Phenotypes Reveals Key Points of Connectivity between Them.Frontiers in physiology · 2017Article
- Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington's Disease: Are They Fit-for-Purpose for Treatment Development?Frontiers in neurology · 2017Review
- Rhythms and blues: modulation of oscillatory synchrony and the mechanism of action of antidepressant treatments.Annals of the New York Academy of Sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is a pleomorphic illness originating from gene x environment interactions. Patients with differing symptom phenotypes receive the same diagnosis and similar treatment recommendations without regard to genomics, brain structure or function, or other physiologic or psychosocial factors. Using this present approach, only one third of patients enter remission with the first medication prescribed, and patients may take longer than 1 year to enter remission with repeated trials. Research to improve treatment effectiveness recently has focused on identification of intermediate phenotypes (IPs) that could parse the heterogeneous population of patients with MDD into subgroups with more homogeneous responses to treatment. Such IPs could be used to develop biomarkers that could be applied clinically to match patients with the treatment that would be most likely to lead to remission. Putative biomarkers include genetic polymorphisms, RNA and protein expression (transcriptome and proteome), neurotransmitter levels (metabolome), additional measures of signaling cascades, oscillatory synchrony, neuronal circuits and neural pathways (connectome), along with other possible physiologic measures. All of these measures represent components of a continuum that extends from proximity to the genome to proximity to the clinical phenotype of depression, and there are many levels along this continuum at which useful IPs may be defined. Because of the highly integrative nature of brain systems and the complex neurobiology of depression, the most useful biomarkers are likely to be those with intermediate proximity both to the genome and the clinical phenotype of MDD. Translation of findings across the spectrum from genotype to phenotype promises to better characterize the complex disruptions in signaling and neuroplasticity that accompany MDD, and ultimately to lead to greater understanding of the causes of depressive illness.
Indexed as
Identifiers
25733956PMC4336921W1505291704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.